Home › News › Clinical Trials › Archive

Clinical Trial News Archive

Get news By email or subscribe to our News feeds.

All News Consumer Pharma New Drugs Pipeline Clinical Trials

December 2007

December 3

Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients Discovery Labs' Aerosurf Improves Lung Function and Reduces Inflammation in a Model of Respiratory Distress Syndrome UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology's 49th Annual Meeting Ceragenix Announces Promising Antimicrobial Coating Data SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology's 49th Annual Meeting MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study Access Pharmaceuticals' ProLindac to be Featured at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy Conference Merck's Rotateq Reduced Hospitalizations and Emergency Department Visits Due to G9P1A(8) Rotavirus by 100 Percent as Shown by Post-hoc Analysis of Data Immunomedics to Present At American Society of Hematology 49th Annual Meeting Bayer AG: Review of Rivaroxaban Data Presented at the 49th Annual Meeting of the American Society of Hematology (ASH) - Investor Conference Call on December 11, 2007 Callisto Announces Presentation on Guanilib at 2007 Crohn's and Colitis Foundation National Research and Clinical Conference Early Treatment with Copaxone Demonstrated Robust Protection Against Progression to Clinically Definite Multiple Sclerosis in the PreCISe Study Targacept Announces Results of Phase II Study of TC-2696 in Postoperative Dental Pain Gemin X Pharmaceuticals to Present Data on Obatoclax at American Society of Hematology Annual Meeting Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Intercell´s Clinical Data on Japanese Encephalitis Vaccine Published in “the Lancet” Aerosol Launches Immune Response in Lungs to Wipe Out Lethal Infections Knopp Neurosciences Presents Results of Phase 1 Ascending Single-Dose Study of KNS-760704 UCB Announces Positive Phase III Trial Results for Keppra XR (levetiracetam) Extended-Release Tablets New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD

December 4

Inhibiton Therapeutics Announces ICA-1 Compound Effective in In-Vitro Testing in Various Cancer Cell Lines Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics Soliris Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients ZymoGenetics to Present at American Society of Hematology Annual Meeting ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting EpiCept Announces Presentation of New Ceplene Data at the 49th Annual Meeting of the American Society of Hematology Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam Genta Clinical Programs Featured at American Society of Hematology Meeting ChemGenex Announces Poster Presentations at the 49th Annual Meeting of the American Society of Hematology Celtic Pharma Reports Data Presented at Society for Neuro-Oncology Annual Meeting and Provides Update on Xerecept Clinical Program Could Hydrogen Sulfide Hold the Key to A Long Life? Cannasat and IntelGenx Complete Phase 1 Study for CAT 310 Study: Re-engineered Gleevec Reduces Heart Risks

December 5

113 Abstracts Evaluating Celgene Products to Be Presented at the 49th American Society of Hematology Meeting Rigel Announces Presentations at the 2007 American Society of Hematology (ASH) Meeting Celtic Pharma Provides Update on XERECEPT Clinical Program Study Data Show Asacol (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint Data from Innovive Pharmaceuticals' Oncology Drug Programs to be Presented at the American Society of Hematology 49th Annual Meeting Journal of the American Medical Association (JAMA) Publishes One-Year Acuity Trial Results AVANT Immunotherapeutics Achieves Immune Responses Against Cholera, Typhoid and Enterotoxigenic E. coli with a Single-Dose, Oral Combination Vaccine Preliminary Results Show Lotemax with Topical Cyclosporine to be Effective for Relief of Dry Eye Signs and Symptoms New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression Updated Analysis of 2001 Epoetin Alfa Study Posted Drug Found to Create New Connections in Brain, Restoring and Improving Memory AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL XR Soliris Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of Pnh Patients Study Data Show Asacol (mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis Pheromones Identified That Trigger Aggression Between Male Mice Scientists Identify Gene That Influences Alcohol Consumption Cyclacel Pharmaceuticals Announces Sapacitabine Poster Presentation at Upcoming American Society of Hematology Meeting Pharmatech, Inc. to Present Preliminary Trial Results at the American Society of Hematology 49th Annual Meeting

December 6

Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine (VNP40101M) at the American Society of Hematology Meeting Pluristem to Present at the Annual Meeting of the American Society of Hematology Monotherapy Byetta Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes Data on PolyMedix's Heptagonist Compounds to be Presented at Annual Meeting of the American Society of Hematology ANAVEX Advances Drug Candidates for Treatment of Epilepsy Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program Cyclacel Pharmaceuticals to Present Sapacitabine Phase I data at US American Society of Hematology Conference Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting SIGA Completes 21 Day Multi-Dose Human Clinical Safety and Dose-Ranging Trial of Its Lead Smallpox Drug ST-246 Remoxy Meets Primary Endpoint in Pivotal Phase III Study Procrit (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting

December 7

Alexion Pharmaceuticals to Present Data on Soliris (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction The International Myeloma Foundation Says Major Medical Conference Points to Improved Treatment and Survival Options for Blood Cancers Xencor Presents Findings on New Aspect of its Fc Technology Targeting Autoimmune Disease Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin Oral Insulin Acusphere Announces that Imagify Safety and ECHO Reader Training Data Will Be Presented at EuroEcho 2007 Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia New Taxotere (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS)

December 10

XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis Preliminary Results from VioQuest Pharmaceuticals' Phase I Trial of Novel Akt Inhibitor VQD-002 in Patients with Advanced Leukemias Demonstrate Promising Clinical Activity BioCryst Announces Presentation of Data Detailing Synergistic Activity of Forodesine HCl With Bendamustine in Chronic Lymphocytic Leukemia (CLL) Micromet and MedImmune Present New Clinical Data for MT103 at the American Society of Hematology Annual Meeting Suggesting Potent Single-Agent Activity in Patients with Relapsed Mantle Cell and Follicular Lymphoma EntreMed Presents Results for Its Lead Aurora Kinase-Angiogenesis Inhibitor Sangamo BioSciences Announces Presentation of Data for ZFP Therapeutic for Glioblastoma at American Society for Hematology Meeting Osiris Therapeutics Reports Positive Results for Prochymal as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease ZymoGenetics Presents Positive Interim Phase 1 Results for IL-21 in Combination with Rituxan in B Cell Lymphoma Dermatologic Surgery Journal Publishes Landmark Study Showing Positive Five-Year Effects of ArteFill for Smile Lines EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene + IL-2 Vion Pharmaceuticals Presents Preliminary Data from its Pivotal Phase II Trial of Cloretazine (VNP40101M) in Acute Myelogenous Leukemia at ASH Annual Meeting Seattle Genetics Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at ASH Pharmacyclics Announces Presentation of Results from Phase 1/2 Trial of Xcytrin Plus Zevalin and Preclinical Data with Novel BTK and HDAC Inhibitors Innovative Research Advances Stem Cell and Bone Marrow Transplantation Xencor Data from Pre-clinical XmAb Antibody Studies Presented at American Society of Hematology Meeting Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractioned Heparin (UFH) Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program Avalon Pharmaceuticals Announces their Beta-catenin Inhibitors Demonstrate Potent Cytotoxic Effects in Multiple Myeloma ASH presentation supports Antisoma's phase II trial in AML ChemGenex Investigators Report Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients With the T315I Mutation Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology Enzon Presents New PEG-SN38 Preclinical Data at ASH Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil Data Indicate That SuperGen's Lead JAK2 Kinase Inhibitors Prevent Cancer Cell Proliferation in Non-clinical Models Speedel Announces Start of SPP635 Phase IIa Trial in Diabetic Patients Avastin is Leading the Way for New Targeted Therapies to Replace Current Cytotoxic Agents as Driving Force in Non-Small-Cell Lung Cancer Market Treanda Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma SuperGen's Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting Genitope Corporation Presents New Data On Its Therapeutic Monoclonal Antibodies To Potentially Treat B-Cell Malignancies Gloucester Pharmaceuticals Announces Positive Interim Results of Phase I/II Study in Patients with Multiple Myeloma at the 2007 American Society of Hematology (ASH) Annual Meeting Gloucester Pharmaceuticals Reports Clinically Significant Responses in Pivotal Trial of Romidepsin for Cutaneous T-cell Lymphoma at the 2007 American Society of Hematology (ASH) Annual Meeting EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models Long-Term Soliris Therapy Improved or Stabilized Kidney Function in Patients With PNH Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery New Study Shows Levitra Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity Celator Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients Long-Term Safety and Efficacy Data on Promacta (Eltrombopag) Presented at American Society of Hematology Annual Meeting Innovive Pharmaceuticals Presents Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at ASH Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2 'Roche to announce new breast cancer data pointing to better survival chances and potential for cure' Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma New Phase 2 Data for Non-EPO Treatment of Anemia S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology Pivotal Phase 3 Nplate Study in Non-Splenectomized Patients Met Primary Endpoints Studies Show Effectiveness of Euflexxa in Treating Knee Osteoarthritis and Reducing the Pain that Interferes with Daily Activities Gentler Chemotherapy Before Blood Stem Cell Transplant Causes Long-Term Complete Remission in Relapsed Follicular Lymphoma Patients Xanthus' Xanafide Bypasses Multi-Drug Resistance Proteins in Acute Myeloid Leukemia Pivotal Phase 3 NPLATE Study in Non-Splenectomized Patients Met Primary Endpoints Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting Data Presented At The American Society Of Hematology 49th Meeting Demonstrate That Incyte's Novel JAK Inhibitor, INCB18424, Provides Rapid and Profound Clinical Benefits in Myelofibrosis Patients Velcade (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial

December 11

ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting Poll of Infection Prevention and Control Professionals Reveals MRSA Prevention Progress Six Months After National Survey Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting Dacogen (Decitabine) for Injection Data Presented at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART AVAX Technologies Announces Successful Completion of Phase I / II Study of MVax in Patients with Stage 3 and 4 Melanoma Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA Aspect Medical Systems Announces Positive Results of BRITE Major Depression National Study ChemGenex Investigators Report Omacetaxine Effective in Killing CML Stem Cells in Animal Model Studies ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors MDS Patients on Five-Day Vidaza Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity Panacos Announces Results of Bevirimat 350 mg Cohort, Data Support Further Dose Escalation in Phase 2b Study The International Myeloma Foundation Says New Findings Reported at Global Cancer Conference Require New Ways to Evaluate Treatments Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma Sunesis Pharmaceuticals Reports Positive Data at ASH Early Phase II Results Show Bosutinib Safe, Effective for CML New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain MMRC Genomics Initiative Selected for Two Presentations At American Society of Hematology Annual Meeting Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated JWCI Researchers Identify Epigenomic Test That Could Improve Treatment for Specific Gastric Cancers Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA

December 12

Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease Once-Daily Exjade Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes Results from Biovitrum's Phase II Clinical Trial of Novel Pain Treatment is Expected to be Presented in Beginning of Second Quarter 2008 Peplin Announces Positive Results of Phase IIa AK Trial Invega Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia New Phase 3 Data Showed Pristiq Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo Scientists Develop New Drug to Outflank Cancer Resistance Nymox Reports Update on NX-1207 Study Results, Marketing Plans and Activities Mayo Clinic Proceedings Article Offers New Data About the Impact of the Shingles Virus on Healthy Adults Pioglitazone Lowers Cardiovascular Risk in Diabetic Patients with Kidney Disease Regulus Therapeutics and Collaborators Discover Role of Viral microRNAs in Cancer and Identify First-Ever Example of a Viral microRNA Oncogene

December 13

Puricase (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study Vanda Presents Phase III Iloperidone Efficacy Data Savient Pharmaceuticals to Release Top-Line Results from Puricase Phase 3 Trials in Treatment-Failure Gout on December 13, 2007 Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery Neose Announces Presentation of GlycoPEGylated Factor VIIa Data at the American Society of Hematology Annual Meeting Genzyme Study of Myozyme for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints Genzyme Study of Myozyme for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints Sirtris Pharmaceuticals' SIRT1 Activator Controls Glucose as Well as a DPP-4 inhibitor in a Pre-Clinical Model of Type 2 Diabetes Patients Given Sunitinib Need Close Monitoring for Cardiac Problems High-Dose Chemotherapy, Autologous Stem Cell Transplantation Shows Little or No Survival Benefit as Adjuvant Therapy for Node-Positive Breast Cancer Taxotere-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer WILEX Announces Positive Result of the Interim Analysis for Futility of its Phase III ARISER Trial with Rencarex Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents Early Results Show Promise in Reducing Side Effects from Anastrozole

December 17

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer Xeloda, Taxotere and Herceptin Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle Data Presented at the 30th San Antonio Breast Cancer Symposium Supports Further Development of INCB7839 as a New Oral Treatment for Breast Cancer New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment Breast Cancer Patients and Oncologists Highly Satisfied with Communication, Yet Disagree on Conversation Priorities Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program Adipose-Derived Stem Cells Show Promise in Breast Reconstruction Anastrozole Confirmed Superior in Breast Cancer Prevention Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy Data Show Arimidex (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer Endo Announces Positive Results From Interim Analysis of Rapinyl Phase III Clinical Trial PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium Actelion Provides Update On Bosentan in Metastatic Melanoma Orexo's Partner Endo Announces Positive Results from Interim Analysis of Rapinyl Phase III Clinical Trial GlaxoSmithKline Announces Data on Tykerb (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases Dynogen Announces Positive Results in Phase 2 IBS-d Study Weitz & Luxenberg Recognizes New Advance in Mesothelioma Treatment Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer Phosphagenics Ltd Announce Successful Transdermal Oxycodone Clinical Trial Results Scientists Find Bowel Cancer Genes That Triple Risk Ablynx reports positive Phase I results for its anti-thrombotic NanobodyR, ALX-0081 New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia New Drug Combination is Able to Eradicate Breast Metastases in Mice

December 20

Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program Ceragenin Compound Demonstrates Potent Activity Against Multidrug Resistant Bacterial Strains of Pseudomonas FASgen Announces New Discovery for Treatment of Stroke Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal for Fabry Disease Collegium Pharmaceutical Inc. Announces Final Study Results of its Successfully Completed Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product Topline Results Announced from a Phase 2 Study in Advanced Melonoma of Investigational Anti-Cancer Drug AZD6244 (ARRY-886) Study Reaffirms Superiority of Trofile Assay Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action Breakthrough in Pulmonary Drug Delivery will Bring Numerous In-Hospital Treatments to the Home A New Treatment Option for Patients with Renal Cancer Genitope Corporation to Host Conference Call to Discuss Initial Results of Phase 3 Clinical Trial

Clinical Trial Results Archive

2005

April

More News Resources

(web5)